Table 1 Model simulation results
From: Is it time for China to prioritize pan-genotypic regimens for treating patients with hepatitis C?
Strategy | Cost ($) | Effectiveness (QALYs) | ICER ($/QALY) | Effectiveness (Cured) | ICER ($/Cured) | Number of new cases | ||
|---|---|---|---|---|---|---|---|---|
DC | HCC | LT | ||||||
Gene-specific treatment | 2869 | 13.756 | Â | 93699 | Â | 2003 | 3874 | 261 |
Pan-genotype treatment | 3034 | 13.886 | 1268 | 99567 | 2812 | 270 | 1372 | 57 |